Viral vector-mediated gene therapy for Parkinson's disease

Clinical Neuroscience Research

Volumn 1, Issue 6, 2001, Pages 496-506

  Emborg, Marina E ^a   Deglon, Nicole ^b   Leventhal, Liza ^a   Aebischer, Patrick ^b,c   Kordower, Jeffrey H ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b University of Lausanne Medical Center   (Switzerland)

^c EPFL   (Switzerland)

Author keywords

Dopamine; Gene therapy; Glial cell derived neurotrophic factor; Parkinson's disease

Indexed keywords

EID: 0347156579     PISSN: 15662772     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1566-2772(01)00027-5     Document Type: Review

References (50)

1. Verma IM, Somia N. Gene therapy: promises, problems and prospects. Nature 1997;389:239-242.
2. Cooper JR, Bloom FE, Roth RH. The Biochemical basis of Neuropharmacology, New York: Oxford University Press, 1991. pp. 285-337.
3. Ono T, Fujino T, Tsuchiya T, Tsuda T. Plasmid DNAs directly injected into mouse brain with lipofectin can be incorporated and expressed by brain cells. Neurosci Lett 1990;117:259-263.
4. Jiao S, Acsadi G, Jani A, Felgner P, Wollf J. Persistence of plasmid DNA and expression in rat brain cells in vivo. Exp. Neurol. 1992;115:400-413.
5. Jiao S, Cheng L, Wolff J, Yang N-S. Particle bombardment-mediated gene transfer and expression in rat brain tissues. Biotechnology 1993;11:497-502.
6. Cheng L, Ziegelhoffer P, Yang N-S. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci USA 1993;90:4455-4459.
7. Roessler B, Davidson B. Direct plasmid mediated transfection of adult murine brain cells in vivo using cationic liposomes. Neurosci Lett 1994;167:5-10.
8. Imaoka T, Date I, Ohmoto T, Nagatsu T. Significant behavioral recovery in Parkinson's disease model by direct intracerebral gene transfer using continuous injection of a plasmid DNA-liposome complex. Hum Gene Ther 1998;9:1093-1102.
9. Horellou P, Vigne E, Castel M-N, et al. Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease. NeuroReport 1994;6:230-232.
10. Kaplitt MG, Leone P, Samulski RJ, et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994;8:148-154.
11. During MJ, Naegele JR, O'Malley KL, Geller AI. Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 1994;266:1399-1403.
12. Leone P, McPhee SW, Janson SG, et al. Multi-site partitioned delivery of human tyrosine hydroxylase gene with phenotypic recovery in Parkinsonian rats. NeuroReport. 2000;11:1145-1151.
13. Mandel RJ, Rendahl KG, Spratt SK, et al. Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J Neurosci 1998;18:4271-4284.
14. Fan DS, Ogawa M, Fujimoto KI, et al. Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors. Hum Gene Ther 1998;9:2527-2535.
15. During MJ, Samulski RJ, Elsworth JD, et al. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gen Therapy 1998;5:820-827.
16. Shen Y, Muramatsu SI, Ikeguchi K, et al. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther 2000;11:1509-1519.
17. Leff SE, Spratt SK, Snyder RO, Mandel RJ. Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease. Neuroscience 1999;92:185-196.
18. Bankiewicz KS, Eberling JL, Kohutnicka N. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 2000;164:2-14.
19. Collier TJ, Sortwell CE. Therapeutic potential of nerve growth factors in Parkinson's disease.Drugs Aging 1999;14:261-287.
20. Kordower JH, Palfi S, Chen E-Y, Ma S, et al. Clinico-pathological findings following intraventricular GDNF treatment in a patient with Parkinson's disease. Ann Neurol 1999;46:419-424.
21. Bjorklund A, Kirik D, Rosenblad C, et al. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res. 2000;886:82-98.
22. Bilang-Bleuel AF, Revah P, Colin I, et al. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc. Natl Acad Sci USA 1997;94:8818-8823.
23. Choi-Lundberg DL, Lin Q, Chang YN, et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997;275:838-841.
24. Choi-Lundberg DL, Lin Q, Schallert T, et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Exp Neurol 1998;154:261-275.
25. Lapchak PA, Araujo DM, Hilt DC, Sheng J, Jiao S. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease. Brain Res 1997;777:153-160.
26. Connor B, Kozlowski DA, Schallert T, et al. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and the aged Parkinsonian rat. Gene Ther 1999;6:1936-1951.
27. Kozlowski DA, Connor B, Tillerson JL, Schallert T, Bohn MC. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections. Exp Neurol 2000;166:1-15.
28. Davidson BL, Doran SE, Shewach DS, et al. Expression of Escherichia coli beta-galactosidase and rat HPRT in the CNS of Macaca mulatta following adenoviral mediated gene transfer. Exp Neurol 1994;125:258-267.
29. Bohn MC, Choi-Lundberg DL, Davidson BL, et al. Adenovirus-mediated transgene expression in nonhuman primate brain. Hum Gene Ther 1999;10:1175-1184.
30. Lawrence MS, Foellmer HG, Elsworth JD, et al. Inflammatory responses and their impact on beta-galactosidase transgene expression following adenovirus vector delivery to the primate caudate nucleus. Gene Ther. 1999;6:1349-1350.
31. Kozlowski DA, Bremer E, Redmond Jr. DE, Bohn MC. Quantitative analysis of transgene protein, mRNA, and vector DNA following injection of an adenoviral vector harboring glial cell line-derived neurotrophic factor into the primate caudate nucleus. Mol Ther 2001;3:256-261.
32. Leff SE, Spratt SK, Snyder RO, Mandel RJ. Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease. Neuroscience 1999;92:185-196.
33. Lo WD, Qu G, Sferra TJ, et al. Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression. Hum Gene Ther 1999;10:201-213.
34. Kirik D, Rosenblad C, Bjorklund A, Mandel RJ. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 2000;20:4686-4700.
35. Mandel RJ, Spratt K, Snyder RO, Leff SE. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci 1997;94:14083-14088.
36. Mandel RJ, Snyder RO, Leff SE. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease. Exp Neurol 1999;160:205-214.
37. Naldini L, Blomer U, Gage FH, Trono D, Verma IM. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Proc Natl Acad Sci 1996;93:11288-11382.
38. Naldini L, Blömer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272:263-267.
39. Kordower JH, Bloch J, Ma SY, et al. Lentiviral gene transfer to the non human primate nigrostriatal system. Exp Neurol 1999;160:1-16.
40. Bensadoun JC, Deglon N, Tseng JL, Ridet JL, Zurn AD, Aebischer P. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Exp Neurol 2000;164:15-24.
41. Deglon N, Tseng JL, Bensadoun JC, et al. Self inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum Gene Ther 2000;11:179-190.
42. Kordower JH, Emborg ME, Bloch J, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000;290:767-773.
43. Emborg ME, Ma SY, Mufson EJ, et al. Age-related declines in nigral neuronal function correlate with motor impairments in Rhesus monkeys. J Comp Neurol 1998;401:253-2651.
44. Kordower JH, Bloch J, Chu YP, et al. Lentiviral gene transfer to the non human primate nigrostriatal system. Exp Neurol 1999;160:1-16.
45. Kordower JH, Liu YT, Winn S, Emerich DF. Encapsulated PC12 cell transplants into hemiparkinsonian monkeys: a behavioral, neuroanatomical and neurochemical analysis. Cell Transpl 1995;4:155-171.
46. Emborg-Knott ME, Domino EF. MPTP induced asymmetric parkinsonism in non human primates 6-8 years after a unilateral intracarotid (ica) dose. Exp Neurol 1998;152:214-220.
47. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline responsive promoters. Proc Natl Acad Sci 1992;11:5185-5190.
48. Wade TV, Schneider JS. Distribution of GAD 65/67 mRNA in the pallidal complex in normal and parkinsonian monkeys relevance for the design of a novel gene-based therapy for parkinsonism. Soc Neurosci Abst 2000;26:1291.
49. Yamada M, Oligino T, Mata M, et al. Herpes simplex virus vector-mediated expression of bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo. Proc Natl Acad Sci USA 1999;96:4078-4083.
50. Hurtado-Lorenzo A, Millan E, Castro M, et al. Adenovirus-mediated gene transfer of SHH, GLI-1 and NURR1 in a rat model of Parkinson's disease. Soc Neurosci Abst 2000;26:1796.